Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:21:13 EDT Mon 07 Jul 2025
Enter Symbol
or Name
USA
CA



Q:BCLI - BRAINSTROM CELL THERAPEUTICS - https://www.brainstorm-cell.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BCLI - Q1.21.13·1.140.11.13-0.03-2.6102.01072641.16  1.19  1.136.45  0.723313:02:43Jun 1615 min RT 2¢

Recent Trades - Last 10 of 264
Time ETExPriceChangeVolume
13:02:43Q1.13-0.031,165
13:02:43Q1.13-0.031,125
13:02:41Q1.14-0.02100
13:01:21Q1.132-0.028400
12:57:15Q1.13-0.031
12:56:44Q1.14-0.0245
12:56:27Q1.14-0.02100
12:56:27Q1.14-0.02100
12:56:13Q1.14-0.021,000
12:52:40Q1.14-0.0210

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-16 08:30U:BCLINews ReleaseBrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn(TM)
2025-05-27 07:00U:BCLINews ReleaseBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn(TM) Phase 3b ALS Clinical Trials
2025-05-19 07:00U:BCLINews ReleaseBrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn(TM) for ALS
2025-05-15 16:05U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-15 07:30U:BCLINews ReleaseBrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19
2025-05-07 06:30U:BCLINews ReleaseBrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
2025-05-06 07:00U:BCLINews ReleaseBrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
2025-04-29 06:30U:BCLINews ReleaseBrainStorm's NurOwn(TM) Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting
2025-04-10 07:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn(TM) in ALS
2025-03-31 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
2025-03-26 08:15U:BCLINews ReleaseBrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
2025-03-24 07:00U:BCLINews ReleaseBrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update
2024-12-30 08:00U:BCLINews ReleaseBrainStorm Issues 2024 Letter to Shareholders
2024-12-09 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update
2024-12-03 07:00U:BCLINews ReleaseBrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
2024-12-02 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024
2024-11-14 16:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
2024-11-11 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn(TM) Phase 3b Trial Manufacturing
2024-10-30 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
2024-10-28 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn(TM) Expanded Access Program at 2024 Annual NEALS Meeting